Depression, anxiety, and fear of COVID-19 in patients with multiple sclerosis in pandemic era: a cross-sectional study.
Mohammad AlirezaeiSharareh EskandariehMohammad Ali SahraianAbdorreza Naser MoghadasiPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2021)
The overall prevalence of depressive symptoms in PWMS in our MS clinic is 51.4% which is obviously higher than other world's centers which could be due to fear of COVID-19. In addition to fear of COVID-19, presence of depressive symptoms in PWMS is related significantly with level of education, number of hospital admissions due to MS relapses, and marital status. Other side, the patients classified as suffering from anxious symptoms had more severe problems on fear of COVID-19. But it is recommended for future studies to compare patients score in the COVID-19 era with their score before this pandemic.
Keyphrases
- coronavirus disease
- sars cov
- depressive symptoms
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- sleep quality
- mass spectrometry
- healthcare
- multiple sclerosis
- respiratory syndrome coronavirus
- prognostic factors
- risk factors
- peritoneal dialysis
- mental health
- social support
- primary care
- patient reported
- current status